High FLI1 levels correlated with adverse overall survival (OS) in all AML patients (excluding t[15;17]) (p = 0.00058) and CN-AML (p = 0.044) (Fig. 6a). This evidence concerns the gene FLI1 and acute myeloid leukemia.